PMID: 15373995Sep 18, 2004Paper

Extreme thrombocytopenia following abciximab therapy

Revista española de cardiología
Rocío M Aragonés ManzanaresJosé L Castillo Castro

Abstract

Antagonists of the glycoprotein IIb/IIIa receptor block the binding of fibrinogen and Von Willebrand factor to the platelet receptor. This effect can lead to bleeding and thrombocytopenia. We analyzed the incidence and clinical repercussions of severe thrombocytopenia (< 20 000 /microl) secondary to abciximab treatment in a prospective study of 375 patients (74% men) who underwent percutaneous coronary revascularization and received abciximab at our hospital. We recorded clinical and demographic characteristics, angiographic findings, laboratory results and platelet counts (before, 4 hours after and 12 hours after the procedure) and hematocrit. The incidence of severe acute thrombocytopenia was 1.1%. All patients were men, and none had relevant bleeding complications. Management consisted of monitoring the bleeding, discontinuing the drug and transfusing platelets. Clinicians should be alert to this complication during the initial hours after the administration of abciximab.

References

Nov 15, 1996·The American Journal of Cardiology·D J KereiakesJ P Runyon
Feb 18, 1997·Circulation·S D BerkowitzJ E Tcheng
Sep 11, 1999·The American Journal of Cardiology·K PeterC Bode
Apr 4, 2001·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·M S ReddyD J Kereiakes

❮ Previous
Next ❯

Citations

Jun 25, 2016·Heart & Lung : the Journal of Critical Care·Łukasz PiątekMarianna Janion

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.